Based in Switzerland, at the heart of a dynamic medical industry, Mediliant, an orthopedic contract manufacturer, was created in 2014 through the acquisition of a Zimmer Biomet entity by its management and President Denis Leissing. Mediliant quickly established itself with a full-service offer to customers for their implant production from the management of regulatory phases under multiple standards American, European to the design and machining phases up to cleaning and sterile packaging.

With the support of its shareholders since 2019, Ekkio Capital and its managers, Mediliant has the ambition to become a world leader in orthopedic contract manufacturing specialized in spine, extremity, and trauma implants.

Financial advisor since the first transaction in 2019, Potomac Transactions advised Mediliant and Ekkio Capital on their first acquisition in the United States of Medical Device & Implants (“MDI”) and on the financing of the transaction. Based in Lancaster, Pennsylvania, MDI is a specialist in contract manufacturing extremity implants.

For Mediliant Group, the establishment in the key American market is an important step to quickly reach its first target of $100 million in revenues.